Mirae Asset Global Investments Co., Ltd. Nektar Therapeutics Transaction History

Mirae Asset Global Investments Co., Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$3.04 - $5.14 $70,059 - $118,456	23,046 Added 40.67%	79,706 $255,000
Q2 2022 Jul 26, 2022	BUY	$3.17 - $6.17 $179,612 - $349,592	56,660 New	56,660 $215,000
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $114,396 - $245,366	-6,765 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $32,178 - $37,679	-1,038 Reduced 13.3%	6,765 $240,000
Q1 2019 May 13, 2019	BUY	$31.58 - $46.35 $246,418 - $361,669	7,803 New	7,803 $262,000
Q4 2018 Feb 11, 2019	SELL	$30.43 - $56.65 $234,737 - $436,998	-7,714 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $517,378 - $762,704	-11,136 Reduced 59.08%	7,714 $470,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $143,143 - $323,272	-3,095 Reduced 14.1%	18,850 $921,000
Q1 2018 May 10, 2018	BUY	$57.4 - $108.44 $1.26 Million - $2.38 Million	21,945 New	21,945 $2.33 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.